<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608696</url>
  </required_header>
  <id_info>
    <org_study_id>18C.272</org_study_id>
    <nct_id>NCT03608696</nct_id>
  </id_info>
  <brief_title>Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure</brief_title>
  <acronym>B-PHORE</acronym>
  <official_title>Modeled Dose Exposure of Sublingual Buprenorphine in the Neonatal Opioid Abstinence Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids&#xD;
      in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment&#xD;
      compared to oral morphine. These results were with an empirically derived dose. This study&#xD;
      will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship&#xD;
      and use a rational approach to define an optimal dose regimen. The clinical trial will be&#xD;
      open label, single arm design with a goal of initial testing of a new dosing regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall rationale for this study is to explore new dose regimens in a small number of&#xD;
      patients. There is evidence from pharmacometric models with dose simulation that suggest&#xD;
      there is room for improvement in buprenorphine dosing. This study will explore these doses.&#xD;
      While the endpoint will be primarily pharmacokinetic, it is likely that the revised dose&#xD;
      regimen will be more effective and thus holds the potential for benefit for those infants&#xD;
      participating. This information will be used to feed back to the model and generate&#xD;
      rationally derived, optimal doses to be tested in subsequent efficacy trials.&#xD;
&#xD;
      The neonatal abstinence syndrome (NAS) is a set of signs of withdrawal in an infant with in&#xD;
      utero exposure to opioids. Cardinal manifestations include increased muscle tone, autonomic&#xD;
      instability, irritability, poor sucking reflex, gastrointestinal symptoms, and impaired&#xD;
      weight gain. All infants are treated with non-pharmacologic methods such as swaddling,&#xD;
      rooming in with mother and minimization of stimuli. Despite these measures, ~50% of infants&#xD;
      require pharmacologic treatment to ensure proper growth and development. While the optimal&#xD;
      pharmacologic treatment for NAS has not been identified, expert review identifies an opioid&#xD;
      as the primary therapy. In the US 80% of infants are treated with morphine and 20% with&#xD;
      methadone. Sublingual buprenorphine has been demonstrated to be safe and effective in an open&#xD;
      label phase 1 clinical trial conducted by the Thomas Jefferson University Team [NCT00521248].&#xD;
      These data were used to plan the BBORN (Blinded Buprenorphine OR Neonatal morphine solution)&#xD;
      clinical trial [NCT01452789] comparing buprenorphine to morphine for NAS. BBORN demonstrated&#xD;
      a 40% reduction in length of treatment compared to morphine in a double blind fashion (New&#xD;
      England Journal of Medicine, June 2017). The external validity of this finding has been&#xD;
      supported by retrospective examination of buprenorphine used in a treatment paradigm at the&#xD;
      University of Cincinnati Medical Center, with a reduction in length of treatment of ~30% in&#xD;
      &gt;200 infants.&#xD;
&#xD;
      Dose selection for both the phase 1 trial and the efficacy trial (BBORN) were empirically&#xD;
      derived. A population pharmacokinetic model for buprenorphine in NAS has been published by&#xD;
      our group. In addition a pre-specified endpoint for the BBORN trial was a pharmacokinetic&#xD;
      analysis of buprenorphine. A pharmacokinetic/pharmacodynamic model from the BBORN study has&#xD;
      been published (Clinical Pharmacology and Therapeutics, March 2018). The time to control of&#xD;
      symptoms was directly tied to buprenorphine exposure, which itself appeared to be driven&#xD;
      primarily by clearance. Among the strengths of pharmacometric models is the ability to&#xD;
      simulate in silico many potential dose regimens. In this manner, a dose regimen can be chosen&#xD;
      that is more likely to be in the desired range of concentrations. This approach also allows&#xD;
      for incorporation of covariates of drug exposure or response to treatment. This is much safer&#xD;
      and efficient than the traditional approach of choosing an empiric dose that would need to be&#xD;
      tested in clinical trial. An ideal dose would quickly reach this exposure while maintaining a&#xD;
      good safety margin. There was no evidence of decline in respiratory rate in infants treated&#xD;
      with higher doses of buprenorphine compared to lower doses, or those treated with&#xD;
      buprenorphine compared to those treated with morphine. This may allow a higher initial dose&#xD;
      to more quickly reach therapeutic buprenorphine concentrations. This ultimately could lead to&#xD;
      shorter lengths of treatment and stay, though achieving this goal is outside of the scope of&#xD;
      the current proposed project.&#xD;
&#xD;
      In summary, buprenorphine at the dose and schedule used in prior clinical trials has been&#xD;
      demonstrated to be safe and effective. The goal of the proposed study is to simulate a dose&#xD;
      of sublingual buprenorphine for NAS using pharmacometric modelling techniques. This dose will&#xD;
      be tested in infants requiring treatment for NAS. Pharmacokinetic samples would be collected&#xD;
      and used to confirm and refine the pharmacokinetic model. The proposed study would allow&#xD;
      broad examination and refinement of the exposure/response relationship. This optimized dose&#xD;
      could later be used in an efficacy trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">July 11, 2019</completion_date>
  <primary_completion_date type="Actual">July 11, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Buprenorphine pharmacokinetics</measure>
    <time_frame>Duration of pharmacologic treatment for neonatal abstinence syndrome up to 70 days of age</time_frame>
    <description>Goal is to define buprenorphine pharmacokinetic exposure (Area under the plasma concentration versus time curve (AUC)) in infants treated with buprenorphine for neonatal abstinence syndrome (NAS) using a model-based optimized dose.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants with Treatment Related Adverse Events</measure>
    <time_frame>Duration of pharmacologic treatment for neonatal abstinence syndrome, up to 70 days of age</time_frame>
    <description>The number of participants with treatment related adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of treatment</measure>
    <time_frame>Duration of pharmacologic treatment for neonatal abstinence syndrome up to 70 days of age</time_frame>
    <description>Length of treatment with buprenrophine for NAS (hours) of a model-based optimized dose of buprenorphine for infants treated for NAS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinary metabolites</measure>
    <time_frame>Duration of pharmacologic treatment for neonatal abstinence syndrome up to 70 days of age</time_frame>
    <description>The urinary glucuronidated metabolites of buprenorphine will be identified and quantified</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Neonatal Abstinence Syndrome</condition>
  <condition>Neonatal Opiate Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine 0.075 mg ml sublingual solution&#xD;
Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose &lt; Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>buprenorphine 0.075 mg/ml solution</description>
    <arm_group_label>buprenorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. â‰¥ 36 weeks gestation&#xD;
&#xD;
          2. Exposure to opioids in utero&#xD;
&#xD;
          3. Demonstration of signs and symptoms of neonatal abstinence syndrome requiring&#xD;
             pharmacologic treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major congenital malformations and/or intrauterine growth retardation, defined as&#xD;
             birth weight &lt;2000 gm&#xD;
&#xD;
          2. Medical illness requiring intensification of medical therapy. This includes but is not&#xD;
             limited to suspected sepsis requiring antibiotic therapy.&#xD;
&#xD;
          3. Hypoglycemia requiring treatment with intravenous dextrose&#xD;
&#xD;
          4. Bilirubin &gt;20 mg/dL (The need for phototherapy is not exclusionary)&#xD;
&#xD;
          5. Inability of mother to give informed consent due to co-morbid psychiatric diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter K Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hosptial</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>buprenorphine</keyword>
  <keyword>pharmacometrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neonatal Abstinence Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The sharing plan has not yet been defined</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>October 18, 2021</submitted>
    <returned>November 15, 2021</returned>
    <submitted>November 16, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

